Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This randomized clinical trial will study subcutaneous depot medroxyprogesterone acetate
(DMPA sc) self-administration at two Planned Parenthood affiliates serving diverse patient
populations. Prior studies demonstrate that DMPA self-injection is safe, effective, feasible,
and acceptable for women and adolescents. A total of 400 female patients (ages 15-44)
requesting DMPA will be randomized to self-administration of DMPA sc or clinic administration
(usual care). Subjects will be followed for one year. The primary study outcome is DMPA
continuation at one year by self-report in both study arms. Secondary outcomes include
patient-reported satisfaction with treatment; satisfaction with home use; and costs
associated with contraceptive care. The investigators hypothesize higher continuation rates
among self-injection users compared to patients who receive standard care. Secondary
exploratory hypotheses include higher patient satisfaction and lower costs associated with
contraceptive care among self-injection users.